文献速递白内障与屈光手术眼底病与葡萄膜炎

ErbB受体在晶状体细胞纤维化与继发性白内障中的作用

ErbBs in Lens Cell Fibrosis and Secondary Cataract.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2023-01-01

本研究在鸡晶状体上皮细胞原代培养物中探究ErbB家族受体及其配体的表达,以及TGFβ对ErbB功能的影响。结果显示拉帕替尼等ErbB激酶阻断剂可选择性抑制TGFβ诱导的上皮-肌成纤维细胞转化,TGFβ增加可溶性ErbB配体并改变ErbB表达谱。结论支持ErbB1作为纤维化性后囊膜混浊的治疗靶点。

要点

  • 小分子ErbB激酶阻断剂(包括拉帕替尼)可选择性抑制TGFβ诱导的晶状体细胞上皮-肌成纤维细胞转化。
  • 晶状体细胞组成性表达ErbB1、ErbB2和ErbB4蛋白于质膜并释放ErbB激活配体。
  • TGFβ增加可溶性 bioactive ErbB配体,降低总ErbB2和ErbB4及细胞表面ErbB2和ErbB4,增加ErbB1表达和同源二聚体形成。

核心结论

  • 研究结果支持ErbB1作为纤维化性后囊膜混浊的治疗靶点,可能用于药物性保护数百万白内障患者的视力。

研究设计与样本

  • 研究采用鸡晶状体上皮细胞原代培养物(解离细胞来源的单层培养物,DCDMLs),在基础条件和促纤维化条件下通过免疫荧光显微镜和蛋白质印迹分析。

主要发现

  • 小分子ErbB激酶阻断剂包括人治疗药物拉帕替尼,选择性抑制DCDMLs中TGFβ诱导的上皮-肌成纤维细胞转化。
  • 晶状体细胞组成性表达ErbB1(EGFR)、ErbB2和ErbB4蛋白于质膜,并向培养基中释放ErbB激活配体。
  • 用TGFβ培养DCDMLs增加可溶性 bioactive ErbB配体,并显著改变ErbB:降低总ErbB2和ErbB4及细胞表面ErbB2和ErbB4,同时增加ErbB1表达和同源二聚体形成。
  • 当晶状体细胞暴露于促纤维化基质纤连蛋白时,也诱导类似的TGFβ依赖性ErbB相对表达变化。
  • 单次1小时拉帕替尼处理可抑制6天后评估的DCDMLs上皮-肌成纤维细胞转化;短期暴露于较低剂量拉帕替尼与亚适水平机制不同的多激酶抑制剂联合时,也能引发持久反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: TGFβ-induced epithelial-to-myofibroblast transition (EMyT) of lens cells has been linked to the most common vision-disrupting complication of cataract surgery-namely, posterior capsule opacification (PCO; secondary cataract). Although inhibitors of the ErbB family of receptor tyrosine kinases have been shown to block some PCO-associated processes in model systems, our knowledge of ErbB signaling in the lens is very limited. Here, we investigate the expression of ErbBs and their ligands in primary cultures of chick lens epithelial cells (dissociated cell-derived monolayer cultures [DCDMLs]) and how TGFβ affects ErbB function. METHODS: DCDMLs were analyzed by immunofluorescence microscopy and Western blotting under basal and profibrotic conditions. RESULTS: Small-molecule ErbB kinase blockers, including the human therapeutic lapatinib, selectively inhibit TGFβ-induced EMyT of DCDMLs. Lens cells constitutively express ErbB1 (EGFR), ErbB2, and ErbB4 protein on the plasma membrane and release into the medium ErbB-activating ligand. Culturing DCDMLs with TGFβ increases soluble bioactive ErbB ligand and markedly alters ErbBs, reducing total and cell surface ErbB2 and ErbB4 while increasing ErbB1 expression and homodimer formation. Similar, TGFβ-dependent changes in relative ErbB expression are induced when lens cells are exposed to the profibrotic substrate fibronectin. A single, 1-hour treatment with lapatinib inhibits EMyT in DCDMLs assessed 6 days later. Short-term exposure to lower doses of lapatinib is also capable of eliciting a durable response when combined with suboptimal levels of a mechanistically distinct multikinase inhibitor. CONCLUSIONS: Our findings support ErbB1 as a therapeutic target for fibrotic PCO, which could be leveraged to pharmaceutically preserve the vision of millions of patients with cataracts.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. VanSlyke JK, Boswell BA, Musil LS, et al. ErbBs in Lens Cell Fibrosis and Secondary Cataract. Invest Ophthalmol Vis Sci. 2023. PMID: 37418274. doi:10.1167/iovs.64.10.6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。